Mercer Global Advisors
CRNX icon

Mercer Global Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Mercer Global Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Buy
+4,136
New +$154K ﹤0.01% 3479

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Mercer Global Advisors's CRNX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 4,136 shares worth $155K. The stake represents ﹤0.01% of the portfolio and ranks #3479 among its holdings.

250 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Mercer Global Advisors held 4,136 shares of Crinetics Pharmaceuticals worth $155K as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Mercer Global Advisors position in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3479 holding.
  • 250 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.